FloLipid Withdrawal: FDA Moves to Pull the First US Liquid Statin Over Missing Annual Reports
FDA has proposed withdrawing approval of Salerno Pharmaceuticals’ FloLipid simvastatin suspension after repeated missing annual reports. Hearing deadline 18 December.
